Well, I must admit that's a compelling thought as well...Dr Max is a GSK guy from years back, before he was sent over to ViiV, which as you know is still basically GSK, since they own ViiV.
The case to be made there is that GSK's PD-1 blocker Jemperli came several years later to market than Keytruda, and they really need to broaden the clinical footprint of that drug; a tumor environment modifier/immune primer like leronlimab could be a low cost, slam dunk addition for them.